Acer Therapeutics Inc. (NASDAQ:ACER) Expected to Earn FY2022 Earnings of ($1.69) Per Share

Acer Therapeutics Inc. (NASDAQ:ACERGet Rating) – Research analysts at HC Wainwright upped their FY2022 earnings per share (EPS) estimates for shares of Acer Therapeutics in a report issued on Monday, November 21st. HC Wainwright analyst V. Bernardino now expects that the biopharmaceutical company will post earnings of ($1.69) per share for the year, up from their previous estimate of ($3.16). The consensus estimate for Acer Therapeutics’ current full-year earnings is ($1.66) per share. HC Wainwright also issued estimates for Acer Therapeutics’ Q4 2022 earnings at ($0.42) EPS and FY2023 earnings at ($1.10) EPS.

Acer Therapeutics Stock Performance

Shares of NASDAQ ACER opened at $1.17 on Wednesday. The stock has a market cap of $18.65 million, a price-to-earnings ratio of -0.82 and a beta of 1.21. The business has a 50 day simple moving average of $1.29 and a 200 day simple moving average of $1.53. Acer Therapeutics has a 52 week low of $1.11 and a 52 week high of $3.77.

Institutional Investors Weigh In On Acer Therapeutics

Several large investors have recently made changes to their positions in the company. Renaissance Technologies LLC lifted its holdings in Acer Therapeutics by 216.8% in the 2nd quarter. Renaissance Technologies LLC now owns 69,700 shares of the biopharmaceutical company’s stock worth $88,000 after purchasing an additional 47,700 shares during the last quarter. Copperwynd Financial LLC acquired a new stake in Acer Therapeutics in the 2nd quarter worth approximately $29,000. Finally, Vanguard Group Inc. lifted its holdings in Acer Therapeutics by 55.5% in the 1st quarter. Vanguard Group Inc. now owns 278,215 shares of the biopharmaceutical company’s stock worth $807,000 after purchasing an additional 99,335 shares during the last quarter. Institutional investors own 9.76% of the company’s stock.

Acer Therapeutics Company Profile

(Get Rating)

Acer Therapeutics Inc, a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. Its pipeline includes four clinical-stage candidates comprising EDSIVO for the treatment of vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation; ACER-001, a formulation of sodium phenylbutyrate for the treatment of various inborn errors of metabolism, including urea cycle disorders and maple syrup urine disease; ACER-801 (osanetant) for the treatment of induced Vasomotor Symptoms; and ACER-2820 (emetine), a host-directed therapy against a variety of infectious diseases, including COVID-19.

Featured Stories

Earnings History and Estimates for Acer Therapeutics (NASDAQ:ACER)

Receive News & Ratings for Acer Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acer Therapeutics and related companies with's FREE daily email newsletter.